Eupraxia Pharmaceuticals Inc (EPRX) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Eupraxia Pharmaceuticals Inc stock C$7.63, price C$10.56, that is 27.7% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Eupraxia Pharmaceuticals Inc
EPRX · TOExpensive (fair value 28% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range C$0.9000 – C$12.99 · fair‑value band C$5.72 – C$9.53 · the C$10.56 price screens above the C$7.63 fair value. As of Nov 15, 2026.
Every Wednesday you see whether Eupraxia Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Show moreShow less
The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis.
The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Stock analysis
Eupraxia Pharmaceuticals Inc (EPRX) currently trades at C$10.56, while our estimate is C$7.63, 28% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: C$5.72 (bear) to C$9.53 (bull), the price of C$10.56 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Eupraxia Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$39.3M in FY2025.
Key figures
Market cap C$710M (≈ $496M) Small · EPS (TTM) C$−1.41 · Return on equity −56.4% · Return on assets (EBIT) −83.0% (5-year average) · Free cash flow −C$29.7M · Net cash C$80.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 31% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −28%, EPRX screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Eupraxia Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- Stock screener with 62 metrics
- Undervalued stocks: Canadian Stocks
- Valuation of the Canada market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs EPRX |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs EPRX |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs EPRX |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs EPRX |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs EPRX |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs EPRX |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs EPRX |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs EPRX |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs EPRX |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs EPRX |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Eupraxia Pharmaceuticals Inc (EPRX) overvalued or undervalued?
What is the fair value of EPRX?
What is the quality score of EPRX?
What is the price target for Eupraxia Pharmaceuticals Inc (EPRX)?
What is the Eupraxia Pharmaceuticals Inc stock forecast for 2026?
What is the intrinsic value of Eupraxia Pharmaceuticals Inc (EPRX)?
Is Eupraxia Pharmaceuticals Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of EPRX?
How much is Eupraxia Pharmaceuticals Inc worth?
What do the bullish and bearish scenarios say about EPRX?
How solid is the balance sheet of Eupraxia Pharmaceuticals Inc (EPRX)?
How far is EPRX from its 52-week high?
Which stocks are comparable to Eupraxia Pharmaceuticals Inc?
Is Eupraxia Pharmaceuticals Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Eupraxia Pharmaceuticals Inc (EPRX)?
What should I pay attention to with Eupraxia Pharmaceuticals Inc right now?
Key figures of Eupraxia Pharmaceuticals Inc
How large is the market capitalisation of Eupraxia Pharmaceuticals Inc (EPRX)?
What are the earnings per share of Eupraxia Pharmaceuticals Inc (EPRX)?
What is the return on equity of Eupraxia Pharmaceuticals Inc (EPRX)?
What is the EBIT return on assets of Eupraxia Pharmaceuticals Inc (EPRX)?
How much free cash flow does Eupraxia Pharmaceuticals Inc (EPRX) generate?
How much net cash does Eupraxia Pharmaceuticals Inc (EPRX) hold?
Watch Eupraxia Pharmaceuticals Inc in the live analysis
One click puts Eupraxia Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.